Michael A. Lauer, MD

Steven D. Mawhorter, MD
Department of Infectious Disease, Cleveland Clinic

Michael A. Lauer, MD
Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan

Address: Steven D. Mawhorter, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mawhors@ccf.org

This paper discusses treatment that is “off label,” ie, not FDA-approved.

Steven D. Mawhorter, MD
Department of Infectious Disease, Cleveland Clinic

Michael A. Lauer, MD
Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan

Address: Steven D. Mawhorter, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mawhors@ccf.org

This paper discusses treatment that is “off label,” ie, not FDA-approved.

Steven D. Mawhorter, MD
Department of Infectious Disease, Cleveland Clinic

Michael A. Lauer, MD
Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan

Address: Steven D. Mawhorter, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mawhors@ccf.org

This paper discusses treatment that is “off label,” ie, not FDA-approved.